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Photodynamic therapy is a new treatment that is being 
introduced into the veterinary community. Photodynamic 
therapy is the use of light activated chemotherapy to kill 
cancer cells (Dougherty, 1998). It has already been 
approved by the US Food and Drug Administration to be 
used as a form of cancer treatment in humans, but has not 
been carried over to the veterinary community. That is until 
now. Photodynamic therapy is now being tested in the 
veterinary community in hopes to find the same results that 
the human medical community has when dealing with 
certain types of cancer. They also hope to permanently 
adopt the new procedure into facilities as an alternative 
form of cancer treatment. 
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1.2 Background 
Photodynamic therapy, also known as light activated 
chemotherapy and photochemotherapy, is a method of 
cancer treatment that has recently been approved by the US 
Food and Drug Administration for curative treatment of 
early-stage lung cancer and palliative treatment in humans 
(Dougherty, 1998). Since it has not been adopted into the 
veterinary medical community, veterinarians have no idea 
how the PDT will work on the animal species. Trials are 
now being done to see if veterinarians will get the same 
results as the medical doctors have and if they do, if the 
results will show that it would be worth using PDT 
permanently as an alternative form of cancer treatment. 
They are also concerned with how it will effect the cancer 
in the animal, what the side effects will be to the animal, 
what type of photosensitizer to use, what concentration of 
the photosensitizer to use, how long exposure time should 
be, and what laser intensity should be used. These are all 
2 
things that the veterinarian community has taken into 
consideration and are now running trials, like the one done 
in this paper, to see what the outcome will be (Lucroy, 
2000). 
3 
1.3 Objective of Study 
To see if the Dye laser or the Luma Care laser yields the 
highest percent kill of the K-9 bladder caner cells. To see 
what drug concentration, light intensity, and length of 
exposure time yields the best percent kill in regards to each 
of the lasers. 
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1.4 Definition of Terms 
Media- The substance in which a specific organism lives 
and thrives. 
Cancer cell- A cell that is part of a malignant tumor. 
Carsinoma- An invasive malignant tumor derived from 
epithelial tissue that tends to metastasize to other areas of 
the body. 
Antimycotic- Antibiotic 
Hemacytometer- An instrument for counting the number 
of blood cells in a measured volume of blood. 
Trypsin- A pancreatic enzyme that catalyzes the 
hydrolysis of proteins to form smaller polypeptide units. 
Florescence Light Reader- An instrument used to read 
the amount of Ultraviolet Light that is emitted through 
cells. 
Rocker Platform- An instrument that is used to mix 
substances by using a continuous rocking motion. 
Necrosis- Death of cells or tissues through injury or 
disease, especially in a localized area of the body. 
Neoplastic tissue- An abnormal new growth of tissue in 
animals or plants; a tumor. 
Osteosarcomas- A malignant bone tumor. Also called 
osteogenic sarcoma. 
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Cutaneous- Of, relating to, or affecting the skin. 
Photosensitization- Sensitization of the skin to light, 
usually due to the action of certain drugs, plants, or other 
substances; may occur shortly after administration of the 
drug (phototoxic sensitivity), or may occur only after a 
latent period of from days to months. 
Erythema- Redness of the skin caused by dilatation and 
congestion of the capillaries, often a sign of inflammation 
or infection. 
Sloughing- A layer or mass of dead tissue separated 
from surrounding living tissue, as in a wound, sore, or 
inflammation. 
Hyperthermia- Unusually high body temperature. 
Pharmacokinetics- The process by which a drug is 
absorbed, distributed, metabolized, and eliminated by the 
body. 
Thrombosis- The formation or presence of a thrombus (a 
clot of coagulated blood attached at the site of its 
formation). 
Apoptosis- Cell death 
Lesions- A localized pathological change in a bodily 
organ or tissue. 
Squamous- Resembling a scale or scales; thin and flat 
like a scale. 
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Malignant- Characterized by progressive and 
uncontrolled growth (especially of a tumor). 
Melanoma- A dark-pigmented, usually malignant tumor 
arising from a melanocyte and occurring most commonly 
in the skin. 
Mast Cell- A cell found in connective tissue that 
contains numerous basophilic granules and releases 
substances such as heparin and histamine in response to 
injury or inflammation of bodily tissues. 
Tumor- An abnormal growth of tissue resulting from 
uncontrolled, progressive multiplication of cells and 
serving no physiological function; a 
neoplasm. 
Fibrosarcoma- Malignant tumor derived from 
connective tissue fibroblast. 
Sebaceous- Secreting fat or sebum. 
Metastatic- Transmission of pathogenic microorganisms 
or cancerous cells from an original site to one or more 
sites elsewhere in the body, usually by way of the blood 
vessels or lymphatics. 
Prostatic- Of or pertaining to the prostate gland. 
Morbidity- The rate of incidence of a disease. 
Inappetence- Lack of appetite. 
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Planum Nasale- Hat plane of the nasal. 
Pinnae- The auricle of the ear. 
Eschar- A dry slough, crust, or scab, which separates 
from the healthy part of the body, as that produced by a 
burn, or the application of caustics. 
Emesis- The act of vomiting. 
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1.5 Outline of Work 
The bulk of the paper will be based on the methodology 
that was used in the experiment. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
2.1 History of Photodynamic Therapy 
One of the oldest known methods for using light 
treatment to treat disease is found in the ancient Vedic text 
Atharva-Veda, circa 1400 B.C. It tells about the use of certain 
plant seeds and sunlight to treat vitiligo (Daniell, 1991). In 
1903, the Nobel Prize was given to Danish scientist Niels 
Finsen for using light and eosin to treat lupus vulgaris (Daniell, 
1991). In the same year, Herman von Tappeiner coined the 
phrase "photodynamic therapy" to describe the oxygen-
dependent therapy he discovered when working with light 
reactions (Jesionek, 1903). 
In 1911, hematoporphyrin was discovered to have 
photosynthesizing properties that could be used to activate 
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photodynamic agents in vitro against agents such as 
Plasmodium falciparum, the causative agent in human malaria 
(Hausman, 1911). 
Further development in this area did not occur until the 
mid twentieth century. In the mid twentieth century, Schwartz, 
Winkelman, and Lipson discovered that fluorescence of 
photosynthesizes like hematoporphyrin could detect tumors 
(Dougherty, 1992). It was observed that hematoporphyrin 
accumulated in tumors after systemic administration to rats and 
that upon illumination, caused tumor necrosis (Figge, 1948). 
Since then, the studies that surround this new form of treatment 
has intensified with a host of clinical PDT applications. During 
the last 25 years, thousands of human patients have been treated 
by PDT with outstanding results. 
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2.2 How Photodynamic Therapy Works 
2.2.1 Selectivity of tumor localization of photosensitizers 
For photodynamic therapy to be effective, the 
photosensitizer must selectively localize in neoplastic tissue 
(Lucroy, 2000). The mechanisms involved in the localization 
of photosensitizers to tumors are poorly understood, however; 
the characteristics of the tumor, photosensitizer, and how they 
are delivered are clearly understood and may play a role in how 
the photosensitizer reaches its location (Lucroy, 2000). An 
example of this would be how porphyrins bind to new collagen 
fibers to be taken into the tumor (Musser 1980). 
Localization of photosensitizers to tumor tissue increases 
as the degree of drug hydrophobicity increases (Kessel 1990). 
By incorporating photosensitizers into the liposomes or 
amphiphilic systems, it may increase the photosensitizers 
uptake into the tumors (Jori, 1996). It appears that 
photosensitizers with lipoproteins with low densities seem to 
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release to tumor cells (Allison, 1990). It also appears that the 
lower the pH of the tumor cell, the increase in the lipoproteins 
and cellular uptake of the photosensitizer into the tumor 
(Barrett, 1990). The ideal photosensitizer for the PDT 
treatment would not have any systemic toxicity, it would be 
selectively taken up by the tumor and retained there instead of 
being taken up by the tumor and the surrounding healthy tissue 
(Lucroy, 2000). A number of photosensitizers have been used 
in the veterinary medical community, but only Photofrin has 
been approved by the FDA to be used in humans 
(Dougherty, 1998). 
2.2.2 How laser light is delivered to tumor 
The amount of light wavelength required for the PDT 
therapy depends upon what photosensitizer that is being used 
(Lucroy, 2000). Also, how the light will penetrate the tissue is 
directly related to the wavelength of laser light used (Wilson, 
1985). The laser light can be delivered to the tumor by a 
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number of ways. They include to the surface, interstitial, or 
intraoperative irradiation (Lucroy, 2000). The light is focused 
on the tumor by an optical fiber that has a microlens at the end. 
The optical fibers can be placed directly into the tumor for 
interstitial irradiation by the addition of a cylindrical diffusion 
tip. Optical fibers can also be used in the gastrointestinal tract 
and urinary bladder by the specialized fibers with a flexible 
endoscope (Lucroy, 2000). 
The amount of light dose delivered can be expressed in 
fluence and power density (Grossweiner, 1997). Fluence is the 
amount of light (number of photons) delivered to a given area 
and is expressed as joules per square centimeter (Lucroy, 2000). 
Power density is the rate (number of photons per unit time) at 
which light is delivered to a given area and is expressed as 
watts per square centimeter (Lucroy, 2000). The power density 
and fluence both have an effect on how efficient the PDT 
therapy will be. The lower the power densities are associated 
with higher local tumor control rates and more efficient tumor 
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killing (Moor, 1997). 
2.2.3 Why PDT works within the tumor 
PDT works well in the killing of tumors due to three 
mechanisms. The first mechanism is PDT may directly damage 
tumor cells (Lucroy, 2000). Secondly, PDT induced oxidative 
damage to tumor vasculature may result in stasis of blood flow, 
vascular leakage, and thrombosis formation with tumor death 
(Henderson, 1994). Thirdly, PDT may cause release of 
cytokines and other inflammatory mediators from treated cells, 
which is followed by nonspecific tumor cell killing resulting 
from the rapid flux of neutrophils and other inflammatory cells 
(Korbelik 1996). 
After examination of the tumors that underwent the PDT 
treatment necrosis and apoptosis occurred in the tumor (Zaidi, 
1993). These findings are very important because when a cell 
becomes malignant, it loses its ability to undergo apoptosis. 
This loss of ability is what causes the cells resistancy to 
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ionizing radiation and other antineoplastic drugs (Lucroy, 
2000). It is not certain why PDT seems to trigger the apoptosis 
in the tumors. Studies are being done to try to find the answer 
to this question. 
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2.3 The Application of Photodynamic Therapy in 
Veterinary Medicine. 
The application of PDT into the veterinary medical 
community is new. Photodynamic therapy is still being used in 
the experimental stages with various photosensitizers to see 
which photosensitizers work the best with the patient and with 
the cancer type. The following are a list of a few of the 
photosensitizers being used today and what the outcomes were. 
2.3. l Hematoporphyrin photosensitizers 
Hematoporphyrin photosensitizer and light have 
been used to treat a variety of tumors in 8 dogs and 3 cats 
(Dougherty, 1981 ). The tumors that were treated in this 
experiment included osteosarcoma, squamous cell 
carcinoma, malignant melanoma, mast cell tumor, 
fibrosarcoma, sebaceous gland tumor, and metastatic 
prostatic carcinoma. The animals were given the 
Hematoporphyrin photosensitizer 48 hours before light 
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treatment. The light source used was an argon-pumped 
dye laser with a spectral output of 635 nm was delivered 
through a 200 µm quartz fiber optics inserted into the 
tumors l .5-2cm apart, depending on tumor size. 
Treatment times varied from 20-30 minutes, power 
intensities ranged from 120-900 mW/cm2• Of the 14 
lesions, 12 (86%) were considered responsive. The two 
lesions that were not responsive were the Osteosarcomas 
(Lucroy, 2000). 
In another study, the tumor that was localized 
fraction of the Hematoporphyrin photosensitizer was 
used for PDT of 25 naturally occurring tumors in 14 dogs 
and 6 cats (Cheli, 1987). The animals were given 
Photofrin II and treated with 631 nm laser light 48 hours 
later. By using external light application, 23 tumors were 
treated. One of the 23 tumors was treated by 
intracavitary irradiation, using a flexible endoscope, and 
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1 was treated by interstitial light application. Five of 
those tumors were reduced surgically before PDT was 
applied. The power density ranged from 85-1,000 
mW/cm2 with fluences of 66-960 J/cm2• A follow-up 
was done 6-14 months later. The results were that a 
complete remission was reported for 4 of the 5 tumors 
that were surgically reduced prior to the PDT treatment 
and for 5 of 8 tumors treated with the PDT treatment 
alone. The outcome for the rest of the tumors was not 
reported (Cheli, 1987). 
2.3.2 Aluminum phtalocyanine tetrasulfonate 
Aluminum phtalocyanine tetrasulfonate (AlPcS4) 
is used as a photosensitizer with the PDT treatment ot 
cats with solar-included squamous cell carcinoma of the 
planum nasale and pinnae (Peaston 1993). Eighteen cats 
were used in this study. Within the 18 cats, there were 
19 
19 lesions present. The 19 lesions were treated with 
AlPcS4 and treated 24 hours later with light from and 
argon-pumped dye laser at 675 nm delivered with an 
optical quartz fiber fitted with a microlens. The power 
intensity was 100 mW/cm2, fluence was 100 J/cm2 and 
treatment time was 16 minutes 40 seconds for each cat 
(Peaston 1993). The results were associated with the 
drug admission itself; complete responses were 
approximately 70% of the animals. The adverse effects 
included local, self-limiting tissue swelling, inappetence, 
and eschar formation (Peaston 1993). 
2.3.3 Pheophorbide photosensitizer 
The photosensitizer known as 2-[l-hexyloxyethyl]-
2-diviny-pyropheophorbide-a (HPPH) is now being used 
in clinical trials in veterinary medicine. The first 
published use of HPPH for veterinary PDT was on 61 
cats with naturally occurring squamous cell carcinoma of 
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the planum nasale, pinnae, and facial skin (Mange 1997). 
Each cat was treated with HPPH 24 hours before light 
irradiation with a wavelength of 665 nm was delivered 
through an optical quartz fiber optic fitted with a 
microlens. The power intensity used was 75 m W/cm2 
and fluence was 100 J/cm2• The results of this study 
were that there was a I 00% response rate for superficial 
tumors < 1.5 cm in diameter and an 18% for invasive 
tumors > 1.5 cm in diameter. The adverse effects were 
not shown to be with the administration of the drug itself, 
but substantial morbidity was observed in several cats 
after the PDT treatment (Mange 1997). Other adverse 
effects included erythema, and edema in and around the 
treated are lasting only 3-5 days after treatment. Five of 
the cats that had large lesions developed a cardiac 
decompensation syndrome manifest as acute congestive 
heart failure (Mange 1997). 
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Another study done using HPPH was done in dogs 
that had hemangiopericytoma and oral squamous cell 
carcinoma. Each dog was given HPPH 48 hours before 
they were treated with light therapy. 
Hemangiopericytoma was surgically removed and tumor 
bed and a margin of grossly normal tissue were 
irradiated. Squamous cell carcinoma was surgically 
reduced prior to PDT treatment but only if they were > .5 
cm thick. The laser light was delivered at 665 nm with a 
quartz fiber optic fitted with a microlens and fluence was 
100 J/cm2• The results were that the 11 dogs with 
hemangiopericytomas were considered to have a 
complete response to the treatment with a follow-up time 
of 5.3 months. Four of the 5 dogs with oral squamous 
cell carcinomas were considered to have a complete 
response with a follow-up time of 10.4 weeks. The only 




3.1 Chapter Overview 
This chapter is used to describe each method and what was 
used in the experiment. There was a lot of microbiological 
and general lab techniques used in this experiment. Each 
procedure was performed at Oklahoma State University in 
the Microbiology laboratory. The procedures were either 
performed by me, Dr. Lucroy, or Trisha Ridgeway. Each 
Procedure has its own explanation and is basically the body 
of the thesis. 
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3.2 Research Methodology 
The first thing that was done in the laboratory was the 
preparation of the media so that the K-9 bladder cancer 
cells could grow. The K-9 bladder cancer cells came to us 
in the laboratory from a commercial dealer. They were 
stored in liquid nitrogen until we were ready to use them. 
3.2.1 Preparation of the Media 
We first made the media by adding L-glutamine, 
Fetal Bovine Syrum, and Antimycotic to a 500ml flask. 
We then brought the volume up to 500ml by adding 
RPMI-1640 by using suction filtration to filter out 
impurities. This media is used to feed the cells. After we 
were done with media we stored it in the refrigerator 
until later use. Media will last about two weeks. 
24 
Reagents and Supplies 
L-glutamine 








-Pipetted all of these substances into the 500 ml Flask. 
-Used suction filtration to add the RPMI-1640 to flask. 
-Added this media to the cells to aid in growth of cells. 
-Kept media in a refrigerator. 
-Kept cells in an incubator set at 37 degrees Celsius. 
-500 ml Flask 
-Suction filtration apparatus. 
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3.2.2 Growing of the K-9 Bladder Cancer Cells 
The commercially ordered K-9 Bladder Cancer 
cells were stored in a liquid nitrogen tank until we 
needed them. When we needed a fresh sample of cells, 
we would take the micropipette vile out of the liquid 
nitrogen and place it in a warm water bath so they could 
defrost. We then took a pipette and sucked out the fresh 
K-9 bladder cancer cells and added them to 15 ml of 
media, mixed the solution together, and placed in 
incubator at 37 degrees Celsius to grow cells. We 
checked the growth of the cells each day and changed the 
media daily as well. When the bottom of the flask was 
covered with cells, we then were ready to detach them 
from the bottom of flask, do our cell count, and plate the 
cells. 
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Reagents and Supplies 





-Incubated cells at 37 degrees Celsius to grow cells. 
-Changed the media daily. 
-Flask 250ml 
-Liquid nitrogen tank (cell storage unit) 
3.2.3 Detaching of the K-9 Bladder Cancer Cells 
After the cells had spread across the bottom of the 
250 ml flask, it was time to detach the cells and prepare 
them for cell counting and cell plating. The first step to 
detaching the cells is to suck off the old media and rinse 
the cells twice with a Phosphate Buffered Solution. After 
sucking off the PBS, we added Trypsin to the flask. We 
then set the cells back into the incubator for 
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approximately 5 minutes. We then added media to 
neutralize the Trypsin and mixed the two mixtures 
together well to insure that neutralization had taken 
place. We then used this neutralized solution to take a 
cell count. 
Reagents and Supplies 







-Warmed the PBS, Media, and Trypsin in a warm water 
bath for approximately I 0 minutes. 
-Added 15ml of PBS twice to rinse the cells. 
-Used suction filtration to remove the PBS and Media 
from cells. 
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-Used pipettes to add the PBS, Media, and Trypsin to 
flask. 
-Incubated Trypsin on cells at 37 degrees Celsius for 5 
minutes. 
3.2.4 Cell Counting 
After the cells have been detached and the Trypsin 
neutralized, we take two small drops of the solution and 
placed one drop on each side of the slide or 
hemacytometer. We then placed the cover slip onto the 
slide and placed it under a microscope to count how 
many cells are in the four quadrants. After we found out 
how many cells are in each of the quadrants, we then 
added all of the quadrants together to get a total number 
of cells in flask. We then took that total number and ran 
it through a series of calculations to find out how much 
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media we needed to add to the cell solution so we could 
plate 20,000 cells per plate. 
Reagents and Supplies 
Amount 
Microscope 
Cell solution 2 small drops 
Calculation 
Here is an example of how the calculation was used. 
Upper left quadrant-150 cells 
Lower left quadrant-251 cells 
Upper right quadrant-276 cells 
Lower right quadrant-227 cells 
Total cells: 904 cells 
+ 4 




18,080,000(total cells in flask) 
+100.000 
I 80.8 ml (media needed to be 
added to flask of cell solution so cells can be plated 
20,000 cells per plate) 
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3.2.5 Plating of the K-9 Bladder Cancer Cells 
3.2.5. l Cell Control 
Before treating the cells with the lasers or drug, we 
first needed a control to go by. We got this control by 
taking the cells we grew and counted and did various cell 
concentrations in the petri dishes. We did 6 petri dishes 
with various amounts of cells in them. Incubated them 
overnight, ran them through protein treatment, and then 
through the Florescence light reader to get amount of 
light emitted threw the cells. 
Reagents and Supplies 
50,000 cells per plate 
25,000 cells per plate 
12,500 cells per plate 
6,250 cells per plate 
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Amount 
.5 ml cells solution and 
1.5 ml of media 
.25 ml cell solution and 
l.75ml of media 
.125 ml cell solution and 
1.85 ml of media 
.06 ml of cell solution 
and 2.0 ml of media 
3,125 cells per plate 
1,563 cells per plate 
.03 ml of cell solution 
and 2.0 ml of media 
.03 ml of cell solution 
and 2.0 ml of media 
3.2.5.2 Cell Plating for Rest of Experiments 
This stage was done by running a fresh group of 
cells through the same calculation above, but this time 
we used a set amount of cells per plate in regards to 
the rest of the experiments. The cell amount was as 
followed. 
Reagents and Supplies 
20,000 cells per plate 
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Amount 
20 µl of cell 
solution and 2.0 ml of 
media 
3.2.6 Treating the K-9 Bladder Cancer Cells with HPPH 
We took the fresh group of cells that were plated 
20,000 cells per plate and plated 30 plates of 20,000 cells 
per plate. With these 30 plates, we added different 
concentrations of the HPPH drug to them. We got the 
HPPH drug dilution by taking two small flasks, one with 
2 ml of media and the other with 4 ml of media, and 
adding .2cc of HPPH to the 2ml flask. We then took the 
2 ml flask of media and of .2cc of HPPH and mixed it 
with the 4 ml flask of media. We then took the drug 
amounts out of the 4ml flask. We then incubated plates 
overnight to prepare them to be run with the laser 
treatment and then through the Florescence light reader 
to see what drug concentration had the highest percent 
kill of the cancer cells. The 30 plates and their HPPH 
concentrations are as followed. 
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Reagents and Supplies 
Amount 
6 plates with 0 amount of drug OHPPH 
6 plates with .25 amount of drug 20µ1 HPPH 
6 plates with .5 amount of drug 40µ1 HPPH 
6 plates with 1.0 amount of drug 80µ1 HPPH 
6 plates with 2.0 amount of drug 160µ1 HPPH 
-Incubated plates at 37 degrees Celsius overnight to 
prepare cells for laser treatment. 
-We used a constant of 40 µI of HPPH to treat all of the 
next experiments. 
3.2.7 Treating the K-9 Bladder Cancer Cells with Lasers 
We used two different lasers in treating the K-9 
Bladder caner cells, the Luma Care laser and a Dye laser. 
The Luma Care laser was ran by a specially made light 
bulb, which is what was used to treat the plated K-9 
caner cells. The Dye laser was a lot bigger apparatus that 
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uses a combination of Argon gas with a quartz wire to 
treat the plated K-9 cancer cells. This laser could treat 3 
plates at a time whereas the Luma Care laser could only 
treat I plate at a time. 
3.2.7.1 Dye Laser 
The Dye Laser treated the different plates with 
various amounts of intensities at first. After the plates 
were treated, they were treated with the protein 
treatment and then ran through the florescence light 
reader to determine what laser intensity was the best. 
That was determined by seeing what laser intensity 
was yielding the highest percent kill. The intensities 
on the first experiment varied. They are as stated 
below. 
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-Dye Laser that was stored in the laboratory was used in this 
experiment. 
-After exposure to laser, the cells had new media placed on 
them and then stored back into the incubator at 37 degrees 
Celsius until the next day when protein treatment was ran. 
3.2.7.2 Luma Care Laser 
The Luma Care laser treated the different plates 
with various amounts of intensities at first. After the 
plates were treated, they were treated with the protein 
treatment and then ran through the florescence light 
reader to determine what laser intensity was the best. 
That was determined by seeing what laser intensity 
was yielding the highest percent kill. The intensities 
on the first experiment varied. They are as stated 
below. 
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-Luma Care laser was stored in laboratory until it was ready to 
use. 
- After exposure to laser, the cells had new media placed on 
them and then stored back into the incubator at 37 degrees 
Celsius until the next day when protein treatment was ran. 
3.2.8 Treating the K-9 Bladder Cancer Cells with Protein 
Treatment 
After the lasers were ran on the cells, they were 
prepared to go through the Florescence light reader. In 
order for us to get a good reading, the treated cells had to 
be treated with various proteins so that the light that the 
Florescence light reader gave off could emit through cells 
properly. These reagents were already made when it was 
time for us to use them. The first thing we did was to 
suck off the old media by using suction filtration. We 
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then washed the cells with the PBS and sucked that off 
by suction filtration as well. We then added TCA and 
placed them into the refrigerator for 20 minutes. We then 
removed the TCA by suction filtration and washed cells 
with HAc. We then removed the HAc by suction 
filtration and added SRB and incubated at room 
temperature for 20-30 minutes. After incubation was 
complete we removed the SRB by suction filtration and 
washed 3 times with HAc. We then let trays air dry out 
of direct light for about 30 minutes. After they were dry, 
we added Tris-Base and placed the cells in their petri 
dishes on the rocker platform for 10 minutes. After 10 
minutes, we took the plated cells off of rocker platform 
and pipetted 1 ml of them into a 96 well plate. This plate 
was then placed into the Florescence light reader to be 
read. 
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HAc I ml(3times) 
Tris-Base lml 
-Placed 1 ml of final solution (after the plated cells got off 
the rocker platform) into a 96 well plate 
-The second HAc was used after treatment with SRB 
3.2.9 Running the K-9 Bladder Cancer Cells through the 
Florescence IJght Reader 
After the plated cells were ran through the protein 
treatment, they were placed into a 96 well plate. This 
plate goes inside of the Florescence light reader. This 
plate holds the substances that the florescence light will 
be emitted through to give the percent of how much light 
was allowed to travel through cells. The principal behind 
this is that the more light that is allowed to pass through 
the plated cells, the lower the percent kill. The killed 
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cells will adhere themselves to the plate, not allowing as 
much light to travel through. We set the machine to run 
550 nm of light through the plated cells each time it was 
used. After the machine was ran, we compiled the data 
that it gave us and placed that data on a graph to show 
what drug concentration, laser intensity, and laser 




4.1 Results of Study 
By using .5 ml of the HPPH drug and 192-200 milliwatts 
of power that it gave us the highest percent kill for the Luma 
Care laser. 
By using .5 ml of the HPPH drug, using 1.6 Watts of 
power, and exposing the cancer cells for 666 seconds that this 
combination yielded the highest percent kill of the cancer cells 
with the Dye Laser. 
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CHAPTERV 
SUMMARY AND CONCLUSION 
5.1 Summary 
We found that by experiments we did that by using .5 ml 
of the HPPH drug and 192-200 milliwatts ot power that it gave 
us the highest percent kill for the Luma Care laser. However; 
we are not sure what the correct length of laser exposure time 
would be to give us the highest kill with this combination 
above. 
We found that by experiments we did that by using .5 ml 
ot the HPPH drug, using 1.6 Watts of power, and exposing the 
cancer cells for 666 seconds that this combination yielded the 
highest percent kill of the cancer cells with the Dye Laser. 
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5.2 Conclusion 
If time had permitted, we would of went back and seen if 
doubling the drug concentration on the experiment with the 
different time trials if there would have been initial killing on 
the Luma Care laser instead of initial growth. 




• Different drug concentrations. 
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